Form 4: Clover Health General Counsel Karen Soares Reports Routine Tax-Related Stock Disposition

Clover Health Investments, Corp.'s General Counsel and Secretary, Karen Soares, reported the disposition of 6,404 Class A Common Stock shares on June 15, 2025, to cover tax obligations related to RSU vesting.

Summary

• Karen Soares, General Counsel & Secretary of Clover Health Investments, Corp. (CLOV), reported a transaction on June 15, 2025.
• The transaction involved the disposition of 6,404 shares of Class A Common Stock.
• These shares were automatically withheld to cover tax obligations upon the vesting of 6.25% of her time-based restricted stock units (RSUs).
• The RSUs were originally granted on September 15, 2022.
• The shares were disposed of at a price of $2.89 per share.
• Following this transaction, Karen Soares beneficially owns 1,256,032 shares of Class A Common Stock.
• Remaining RSUs will continue to vest quarterly in equal installments of 6.25%, with the final vesting date on September 15, 2026, contingent on her continued service.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary tax withholding event related to RSU vesting. It is neutral in sentiment as it reflects a standard administrative process rather than a strategic decision to buy or sell shares.

Positives

• The reporting person, Karen Soares, continues to hold a significant number of shares (1,256,032 Class A Common Stock) after the transaction, indicating continued alignment with shareholder interests.
• The transaction is a routine tax withholding event, not a discretionary sale, which suggests stability in insider holdings.
• The ongoing vesting schedule through September 15, 2026, implies continued commitment of the General Counsel to the company.

Negatives

• A reduction of 6,404 shares from the insider's direct beneficial ownership, although for tax purposes.

Future Outlook

The document indicates that remaining restricted stock units (RSUs) will continue to vest quarterly in equal installments of 6.25% until a final vesting date of September 15, 2026, contingent upon the reporting person's continued service to the company.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction, specifically a tax withholding event related to RSU vesting. It does not provide information relevant to broader industry trends or competitive dynamics within the healthcare technology or insurance sectors where Clover Health operates.

Comparison to Industry Standards

• This document is a standard SEC Form 4 filing reporting an insider transaction. It does not contain information that allows for a comparison of company performance or results against global benchmarks or specific comparable companies/projects. The transaction itself (tax withholding upon RSU vesting) is a common practice across publicly traded companies.

Stakeholder Impact

• Shareholders: The disposition of 6,404 shares is a minor administrative event and is unlikely to have a material impact on the overall share structure or market perception. The continued significant holding by the General Counsel may be viewed positively as alignment of interests.
• Employees: The RSU vesting and tax withholding process is a standard component of executive compensation, which may be part of broader employee incentive programs.

Next Steps

• Remaining restricted stock units (RSUs) will vest quarterly in equal installments of 6.25%.
• The final vesting date for the RSUs is September 15, 2026, subject to Karen Soares' continued service.

Key Dates

Keywords

Clover Health Investments, CLOV, SEC Form 4, Insider Transaction, Karen Soares, Restricted Stock Units, RSU Vesting, Tax Withholding, Class A Common Stock, Corporate Governance